The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Primary Sclerosing Cholangitis: Diagnosis, Prognosis, and Management
Open accessAbstract
Primary sclerosing cholangitis (PSC) is a chronic immune-mediated disease of the liver of unclear etiology, characterized by chronic inflammation and fibrosis of bile ducts. It primarily affects middle-aged men and is associated with 4-fold increased mortality as compared with an age- and sex-matched population. Progressive biliary and hepatic damage results in portal hypertension and hepatic failure in a significant majority of patients over a 10- to 15-year period from the initial diagnosis. In addition, PSC confers a markedly increased risk of hepatobiliary cancer, including cholangiocarcinoma and gallbladder cancer, as compared with the general population, and cancer is the leading cause of mortality in patients with PSC. It is associated with inflammatory bowel disease in 70% of patients and increases the risk of colorectal cancer almost 10-fold. Despite significant research efforts in this field, the pathogenic mechanisms of PSC are still incompletely understood, although growing evidence supports the role of genetic and immunologic factors. There are no proven medical therapies that alter the natural course of the disease. Thus, liver transplantation is the only available treatment for patients with advanced PSC, with excellent outcomes in this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a small percentage of patients, CSPH in PSC (in analogy to PBC) may occur early in the disease course, i.e. even in people with PSC with F2 or F3 fibrosis in the absence of full-blown histologic cirrhosis.250”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [250]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Diagnosis and Management of Primary Sclerosing Cholangitis
Chapman, R. W., Fevery, J., Kalloo, A. N., Nagorney, D. M., Boberg, K. M., Shneider, B. L., & Gores, G. J. (2009) · Hepatology · doi:10.1002/hep.23294 · Cited by 1,230
Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy
Ghazale, A., Chari, S. T., Zhang, L., Smyrk, T. C., Takahashi, N., Levy, M. J., Topazian, M. D., Clain, J. E., Pearson, R. K., Petersen, B. T., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.12.009 · Cited by 890
Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.
Broomé, U., Olsson, R., Lööf, L., Bodemar, G., Hultcrantz, R., Danielsson, A., Prytz, H., Sandberg–Gertzén, H., Wallerstedt, S. M., & Lindberg, G. (1996) · Gut · doi:10.1136/gut.38.4.610 · Cited by 816
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis
Loftus, E. V., Harewood, G. C., Loftus, C. G., Tremaine, W. J., Harmsen, W. S., Zinsmeister, A. R., Jewell, D. A., & Sandborn, W. J. (2005) · Gut · doi:10.1136/gut.2004.046615 · Cited by 777
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis
Lindor, K. D., Kowdley, K. V., Luketic, V. A. C., Harrison, E. M., McCashland, T., Befeler, A. S., Harnois, D., Jorgensen, R., Petz, J., Keach, J., et al. (2009) · Hepatology · doi:10.1002/hep.23082 · Cited by 720
Hepatic and extrahepatic malignancies in primary sclerosing cholangitis
Bergquist, A., Ekbom, A., Olsson, R., Kornfeldt, D., Lööf, L., Danielsson, Å., Hultcrantz, R., Lindgren, S., Prytz, H., Sandberg-Gertzén, H., et al. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00288-4 · Cited by 717
Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis
Wiesner, R. H., Grambsch, P. M., Dickson, E. R., Ludwig, J., MacCarty, R. L., Hunter, E. B., Fleming, T. R., Fisher, L. D., Beaver, S. J., & LaRusso, N. F. (1989) · Hepatology · doi:10.1002/hep.1840100406 · Cited by 641
Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: A systematic review
Boonstra, K., Beuers, U., & Ponsioen, C. Y. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.10.025 · Cited by 632
Soetikno, R. M., Lin, O. S., Heidenreich, P. A., Young, H. S., & Blackstone, M. O. (2002) · Gastrointestinal Endoscopy · doi:10.1067/mge.2002.125367 · Cited by 623
Flagged first, then by citations
Research works printed but not linked: 1
- Karlsen, 2009, The Nordic liver transplant registry, Annu Rep, 2012, 2009
Cited by
Sorted by citations
Items 101–119 of 119
Diseases of the Biliary Tract and Gallbladder
Salah, W., & Harrison, M. E. (2016) · Wiley eBooks · doi:10.1002/9781119127437.ch86 · Cited by 1
Diagnosis and Treatment: ERCP in PSC
Srinivasan, N., & Kozarek, R. A. (2014) · Springer eBooks · doi:10.1007/978-3-319-11077-6_22
Autoimmune Lebererkrankungen und deren Überlappungssyndrome
Teufel, A., & Kanzler, S. (2015) · Die Gastroenterologie · doi:10.1007/s11377-014-0977-1
Extraintestinal Manifestations of Crohn’s Disease
FELICE, K. D., & Raffals, L. E. (2015) · Springer eBooks · doi:10.1007/978-3-319-14181-7_19
Crohn's Disease: Clinical Manifestations and Management
MELMED, G. Y., & Targan, S. R. (2015) · Yamada's Textbook of Gastroenterology · doi:10.1002/9781118512074.ch72
Endoscopic Retrograde Cholangiopancreatography and Cholangioscopy in Hepatobiliary Disease
Mönkemüller, K., Schwingel, G. E., Martinez‐Alcala, A., & Jovanović, I. (2017) · Wiley eBooks · doi:10.1002/9781118660799.ch12
Noninvasive and Invasive Imaging of the Liver and Biliary Tract
Das, K. K., Morgan, M. A., & Ginsberg, G. G. (2017) · Wiley eBooks · doi:10.1002/9781119251316.ch3
Badalyan, V., Conklin, L. S., & Snyder, J. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-40181-4.00060-8
Mohan, P., Khan, M. A., & Snyder, J. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-40181-4.00061-x
Amornyotin, S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.102227
Faleck, D. M., & Kelsen, D. P. (2023) · Springer eBooks · doi:10.1007/978-3-031-14744-9_56
Saganek, J., Meglicka, M., Nowakowska, A., Osiecki, M., & Kierkuś, J. (2023) · Pediatria Polska · doi:10.5114/polp.2023.131762
Cholestasis and Biliary Tract Disorders
Kanel, G. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-82533-7.00004-1
Managing Biologic Therapy and Small Molecule Use in IBD Patients during and after Cancer Diagnosis
Eidelberg, A., & Axelrad, J. E. (2025) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-025-00482-8
Demystifying the imaging diagnoses of sclerosing cholangitis
Agarwal, D., Sharma, S., Aswani, Y., Dutta, R., Helavar, R. V., Gadwal, S. K., & Das, C. J. (2026) · Abdominal Radiology · doi:10.1007/s00261-026-05397-1
Wang, M. C., Chong, A. C., Grave, E. C., Tarakji, A., Rahal, K., Nastaskin, L., Kunitsky, A., Saric, K. J., Lee, H., Sahakian, A. B., et al. (2026) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000004024
Communicating Risk and Safety of Inflammatory Bowel Disease Therapies
Axelrad, J. E., Faye, A. S., & Siegel, C. A. (2026) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000004068
Liver Transplantation for Primary Sclerosing Cholangitis: A 20-Year Single-Center Experience
Yazıcı, S. E., Atasever, A., Acar, Ş., & Yuzer, Y. (2026) · Hitit Medical Journal · doi:10.52827/hititmedj.1884545
Metadata
- Authors
- Singh, S., & Talwalkar, J. A.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Talwalkar, Jayant A.
- ORCID
- Singh, Siddharth
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2013-08
- Volume
- 11
- Issue
- 8
- Pages
- 898-907
- ISSN
- 1542-3565 (ISSN-L)
- PMC
- PMC3692584
- OpenAlex
- W2076789082
- Cited by
- 119
- References
- 114
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 6 · 2023: 9 · 2022: 8 · 2021: 5 · 2020: 8 · 2019: 7 · 2018: 10 · 2017: 11 · 2016: 9 · 2015: 13 · 2014: 13 · 2013: 6
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Gastroenterology and Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK056924)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Keywords
- primary sclerosing cholangitis, bile duct inflammation, liver fibrosis, portal hypertension, hepatobiliary cancer, cholangiocarcinoma, gallbladder cancer, inflammatory bowel disease, colorectal cancer risk, liver transplantation, prognosis, pathogenesis, immune-mediated liver disease
- MeSH terms
- Bile Ducts, Gallbladder Neoplasms, Humans, Hypertension, Portal, Liver Neoplasms, Prognosis, Cholangitis, Sclerosing, Liver Transplantation, Liver Failure, Cholangiocarcinoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
